Modulators of the integrated stress pathway

JP2023548169A5Active Publication Date: 2024-11-05CALICO LIFE SCI LLC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526483
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-18
Filing Date
2021-10-29
Publication Date
2024-11-05
Estimated Expiration
2041-10-29

Smart Images

  • Figure 2022094244000001
    Figure 2022094244000001
  • Figure 2022094244000002
    Figure 2022094244000002
  • Figure 2022094244000003
    Figure 2022094244000003
Patent Text Reader

Abstract

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR), and for treating related diseases, disorders, and conditions.
Need to check novelty before this filing date? Find Prior Art

Claims

1. Formula (I): or a pharma- ceutically acceptable salt thereof, During the ceremony, D is a bridged bicyclic cycloalkyl, a bridged bicyclic heterocyclyl, a 4- to 6-membered monocyclic cycloalkyl, a 4- to 6-membered monocyclic heterocyclyl, or a cubanyl, wherein each of the bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, 4- to 6-membered monocyclic cycloalkyl, 4- to 6-membered monocyclic heterocyclyl, or cubanyl has from 1 to 4 R X and when the 4- to 6-membered monocyclic heterocyclyl or bridged bicyclic heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen is optionally substituted by R N1 may be optionally replaced by U is -NR 1 C(O)-, -C(O)NR 1 - or 5- to 6-membered heteroaryl; E is absent, a bond, or -NR 2 C(O)-, -C(O)NR 2 -, 5- to 6-membered heteroaryl, or 5- to 6-membered heterocyclyl, where the 5- to 6-membered heteroaryl or 5- to 6-membered heterocyclyl has 1 to 5 R G and when the 5- to 6-membered heteroaryl or 5- to 6-membered heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen is optionally substituted by R N2 or E is, and Y is a 4- to 9-membered nitrogen-containing monocyclic, bridged bicyclic, fused bicyclic, or spirocyclic heterocyclyl, wherein the 4- to 9-membered nitrogen-containing monocyclic, bridged bicyclic, fused bicyclic, or spirocyclic heterocyclyl has 1 to 5 R G and when a 4- to 9-membered nitrogen-containing monocyclic, bridged bicyclic, fused bicyclic, or spirocyclic heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen is optionally substituted by R N2 may be optionally replaced by L 1 is a bond, C 1 ~C 6 Alkylene, 2- to 7-membered heteroalkylene, -NR N3 - or -O-, where C 1 ~C 6 The alkylene or 2- to 7-membered heteroalkylene is 1 to 5 R L1 may be substituted by L 2 is absent or a bond, C 1 ~C 6 alkylene, 2- to 7-membered heteroalkylene, or -O-, where C 1 ~C 6 The alkylene or 2- to 7-membered heteroalkylene is 1 to 5 R L2 may be substituted by Here, E and L 2 Both cannot be a bond and not exist at the same time. R 1 is hydrogen or C 1 ~C 6 is alkyl, R 2 is hydrogen or C 1 ~C 6 is alkyl, W is an 8- to 10-membered partially unsaturated fused bicyclic ring moiety comprising a 5- to 6-membered heterocyclyl fused to a phenyl or a 5- to 6-membered heteroaryl, where the heterocyclyl has 1 to 4 R W1 and the phenyl or heteroaryl may be optionally substituted by 1 to 4 R at one or more available unsaturated carbons. W2 and when the heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen is optionally substituted by R N4 and where W is bonded to L through an available saturated carbon or nitrogen atom in the heterocyclyl. 2 Binds to A is C 3 ~C 6 cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, 5- to 6-membered heteroaryl, or 8- to 10-membered bicyclic heteroaryl, where C 3 ~C 6 Cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, 5- to 6-membered heteroaryl, or 8- to 10-membered bicyclic heteroaryl may have 1 to 5 R Y and when the 5- to 6-membered heteroaryl or 8- to 10-membered bicyclic heteroaryl contains a substitutable nitrogen moiety, the substitutable nitrogen is optionally substituted by R N5 may be optionally replaced by Each R L1 are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, Amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, oxo, halo, cyano, -OR A , -NR B R C , -NR B C(O)R D , -C(O)NR B R C , -C(O)R D , -C(O)OH, -C(O)OR D , -SR E , -S(O)R D , and -S(O) 2 R D is selected from the group consisting of Each R L2 are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, Amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, oxo, thioxo, halo, cyano, -OR A , -NR B R C , -NR B C(O)R D , -C(O)NR B R C , -C(O)R D , -C(O)OH, -C(O)OR D , -SR E , -S(O)R D , and -S(O) 2 R D is selected from the group consisting of R N1 is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, halo-C 2 ~C 6 Alkyl, Amino-C 2 ~C 6 Alkyl, cyano-C 2 ~C 6 Alkyl, —C(O)NR B R C , -C(O)R D , -C(O)OR D , and -S(O) 2 R D is selected from the group consisting of R N2 is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, halo-C 2 ~C 6 Alkyl, Amino-C 2 ~C 6 Alkyl, cyano-C 2 ~C 6 Alkyl, —C(O)NR B R C , -C(O)R D , -C(O)OR D , and -S(O) 2 R D is selected from the group consisting of R N3 is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, halo-C 2 ~C 6 Alkyl, Amino-C 2 ~C 6 Alkyl, cyano-C 2 ~C 6 Alkyl, —C(O)NR B R C , -C(O)R D , -C(O)OR D , and -S(O) 2 R D is selected from the group consisting of R N4 is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, C 1 ~C 6 Alkyl-C 1 ~C 6 Cycloalkyl, C 1 ~C 6 Alkenyl, —C(O)—C 1 ~C 6 Alkyl, —C(O)—C 1 ~C 6 Cycloalkyl, C 1 ~C 6 Alkyl-CO 2 H.C. 1 ~C 6 Alkyl-CO 2 -C 1 ~C 6 Alkyl, —C(O)—C 1 ~C 3 Alkyl-O-C 1 ~C 3 Alkyl-O-C 1 ~C 3 Alkyl, -C(O)-phenyl, -C(O)-heteroaryl, -C(O)-heterocyclyl, -S(O) 2 -C 1 ~C 6 Alkyl, -S(O) 2 -phenyl, -S(O) 2 -heteroaryl, -C(O)NR B R C and -C(O)OR D wherein: C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, C 1 ~C 6 Alkyl-C 1 ~C 6 Cycloalkyl, C 1 ~C 6 Alkenyl, C(O)-C 1 ~C 6 Alkyl, —C(O)—C 1 ~C 6 Cycloalkyl, C 1 ~C 6 Alkyl-CO 2 H.C. 1 ~C 6 Alkyl-CO 2 -C 1 ~C 6 Alkyl, -C(O)-heterocyclyl, and -S(O) 2 -C 1 ~C 6 The alkyl may be optionally substituted with one or more substituents, each of which may be independently fluoro, hydroxyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Alkyl (optionally substituted by 1, 2, or 3 fluorine atoms), and S(O) w C 1~6 alkyl (wherein w is 0, 1, or 2); and -C(O)-phenyl, -C(O)-heteroaryl, -S(O) 2 -phenyl, and -S(O) 2 Heteroaryl can be optionally substituted with one or more substituents, each of which is independently selected from halogen, hydroxyl, C 1 ~C 6 alkyl (optionally substituted by 1, 2 or 3 fluorine atoms), C 1 ~C 6 Alkoxy (optionally substituted by 1, 2 or 3 fluorine atoms), and S(O) 2 -NR B R C is selected from the group consisting of R N5 is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, halo-C 2 ~C 6 Alkyl, Amino-C 2 ~C 6 Alkyl, cyano-C 2 ~C 6 Alkyl, —C(O)NR B R C , -C(O)R D , -C(O)OR D , and -S(O) 2 R D is selected from the group consisting of Each R W1 are independently hydrogen, C 1 ~C 6 Alkyl (-CO 2 H), hydroxy-C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl-O-, halo-C 1 ~C 6 Alkyl, Amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, oxo, C=N-OH, halo, cyano, -OR A , -NR B R C , -NR B R CC , -NR B C(O)R D , -C(O)NR B R C , -C(O)R D , -C(O)OH, -C(O)OR D , -SR E , -S(O)R D , and -S(O) 2 R D is selected from the group consisting of Each R W2 are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl-O-, halo-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkoxy, amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, halo, cyano, -OR A , -NR B R C , -NR B C(O)R D , -C(O)NR B R C , -C(O)R D , -C(O)OH, -C(O)OR D , -S(R F ) m , -S(O)R D , and -S(O) 2 R D or Two R on adjacent atoms W2 The groups, together with the atoms to which they are attached, form a 3- to 7-membered fused cycloalkyl, a 3- to 7-membered fused heterocyclyl, a fused aryl, or a 5- to 6-membered fused heteroaryl, each of which is represented by 1 to 5 R X may be substituted by Each R X are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkoxy-C 1 ~C 6 Alkylene, Amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, oxo, halo, cyano, -OR A , -NR B R C , -NR B C(O)R D , -C(O)NR B R C , -C(O)R D , -C(O)OH, -C(O)OR D , -SR E , -S(O)R D , and -S(O) 2 R D is selected from the group consisting of Each R Y are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkoxy-C 1 ~C 6 Alkylene, Amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, halo, cyano, oxo, -C 1 ~C 6 Alkylene-OR A , -OR A , -NR B R C , -NR B R CC , -NR B C(O)R D , -C(O)NR B R C , -C(O)R D , -C(O)OH, -C(O)OR D , -S(R F ) m , -S(O)R D , -S(O) 2 R D , and G 1 or Two R on adjacent atoms Y The groups, together with the atoms to which they are attached, form a 3- to 7-membered fused cycloalkyl, a 3- to 7-membered fused heterocyclyl, a fused aryl, or a 5- to 6-membered fused heteroaryl, each of which is represented by 1 to 5 R X may be substituted by Each G 1 is independently 3- to 7-membered cycloalkyl, 3- to 7-membered heterocyclyl, aryl, or 5- to 6-membered heteroaryl, where each of the 3- to 7-membered cycloalkyl, 3- to 7-membered heterocyclyl, aryl, or 5- to 6-membered heteroaryl is selected from 1 to 3 R Z may be substituted by Each R Z is independently 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, halo, cyano, -OR A , -NR B R C , -NR B C(O)R D , -C(O)NR B R C , -C(O)R D , -C(O)OH, -C(O)OR D , and -S(O) 2 R D is selected from the group consisting of R A is, in each occurrence, independently hydrogen, C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkoxy-C 1 ~C 6 Alkylene, C 1 ~C 6 Alkoxy-C 1 ~C 6 Alkylene, -C(O)NR B R C , -C(O)R D or -C(O)OR D and R B and R C Each of is independently hydrogen or C 1 ~C 6 is alkyl, or R B and R C together with the atoms to which they are attached, 1 to 3 R Z forming a 3- to 7-membered heterocyclyl ring optionally substituted by Each R CC is independently hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkoxy-C 1 ~C 6 Alkylene, C 1 ~C 6 Alkyl-CO 2 H.C. 1 ~C 6 Alkyl-CO 2 -C 1 ~C 6 Alkyl, C(O)C 1 ~C 6 Alkyl, S(O) 2 -C 1 ~C 6 and 3- to 6-membered cycloalkyl and 4- to 6-membered heterocyclyl, wherein the 3- to 6-membered cycloalkyl and 4- to 6-membered heterocyclyl may be optionally substituted by one or more substituents, each of which is independently selected from the group consisting of C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 selected from the group consisting of alkyl, hydroxyl, halo, and -C(O)OH; Each R D is independently 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, or halo-C 1 ~C 6 Alkoxy-C 1 ~C 6 is alkylene, Each R E are independently hydrogen, C 1 ~C 6 Alkyl or halo-C 1 ~C 6 is alkyl, Each R F are independently hydrogen, C 1 ~C 6 alkyl, or halo; Each R G are independently hydrogen, C 1 ~C 6 alkyl, halo, or oxo; and m is R F is hydrogen or C 1 ~C 6 1 for alkyl, and R F C 1 ~C 6 3 when alkyl, or R F is 5 for halo, A compound or a pharma- ceutically acceptable salt thereof.

2. D.

2. The compound of claim 1 selected from the group consisting of:

3. D.

3. The compound of claim 2 selected from the group consisting of:

4. U is *-NHC(O)-, *-C(O)NH-, and 2. The compound of claim 1, wherein the compound is selected from the group consisting of:

5. L 1 is a bond or C 1 ~C 6 alkylene, where C 1 ~C 6 Alkylene is 0 to 5 R L1 2. The compound of claim 1 , substituted by:

6. W is represented by the formula (W-a): wherein: X is O, NR N4 , or C(R X1 ) (R X2 ) and R N4 is hydrogen or C 1 ~C 6 is alkyl, R X1 is hydrogen or hydroxyl, R X2 is hydrogen or hydroxyl, or R X1 and R X2 together form an oxo moiety, The compound of claim 1.

7. W, is selected from the group consisting of Optionally, each R W2 is independently bromo, chloro, fluoro, or --CF 3 ; The compound according to claim 6.

8. The compound of claim 1 , wherein E is absent.

9. E is a bond, *-NR 2 C(O)-, *-C(O)NR 2 -, is selected from the group consisting of Optionally, R 2 is hydrogen; The compound of claim 1.

10. L 2 is a bond, -O-, C 1 ~C 6 alkylene, or 2- to 7-membered heteroalkylene, where C 1 ~C 6 Alkylene or 2- to 7-membered heteroalkylene is 1 to 5 R L2 and each R L2 are independently hydrogen, C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, oxo, thioxo, halo, -OR A 2. The compound of claim 1 selected from the group consisting of:

11. L 2 is a bond, -CH 2 --, --CH 2 O-*, -C(O)-, -C(S)-, -OCH 2 C(O)-*, -C(O)NH-*, -OCH 2 -*, -OCH 2 11. The compound of claim 10, which is C(O)NH-*, or -O-, where "*" represents the point of attachment to A.

12. L 2 The compound of claim 1 , wherein

13. A, is selected from the group consisting of Optionally, R X is -CH 2 CH 2 OCF 3 and each R N5 is independently -C(O)CH 3 , -CF 3 , or -CH 2 CF 3 ; The compound of claim 1.

14. Each R Y are independently hydrogen, chloro, fluoro, hydroxyl, phenyl, oxo, -CHF 2 , -CF 3 , -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -OCH 3 , -OCHF 2 , -OCF 3 , -OCH 2 CF 3 , -OCH(CH 3 ) 2 , -CH 2 O.C.F. 3 , -CH 2 OCH 2 CF 3 , -CH 2 OCH 3 , -CH 2 CH 2 CH 2 O.C.F. 3 , -CH 2 CH 2 CH 2 CH 2 O.C.F. 3 , -CN, -OCH 2 CH 3 , -OCH 2 CH 2 CH 2 CF 3 , -OCH 2 CH 2 CH 2 C (CH 3 ) F 2 , -CH 2 CHF 2 , -CH 2 CF 3 , -CH 2 CH 2 CH 2 CF 3 , -NHCH 2 CH 2 O.C.F. 3 , -NHCH 2 CH 2 CH 2 O.C.F. 3 , -N(CH 3 ) CH 2 CH 2 O.C.F. 3 , -N(CH 3 ) CH 2 CH 2 CH 2 O.C.F. 3 , -N(CH 3 )CH(CH 3 ) CH 2 O.C.F. 3 , -OCH 2 CH 2 O.C.F. 3 , -OCH 2 CH 2 O.C.F. 2 , -OCH 2 CH 2 OCH 3 , -OCH 2 CH 2 CH 2 O.C.F. 3 , -OCH 2 CH 2 OCH 2 CF 3 , -OCH(CH 3 ) CH 2 O.C.F. 3 , -OCH 2 CH (CH 3 ) O.C.F. 3 , -CH 2 OCH 2 CH 2 O.C.F. 3 , -C(O)CH 2 O.C.F. 3 , -CH 2 O.C.(O)O.C.H. 2 CH 3 2. The compound of claim 1, wherein the aryl group is selected from the group consisting of cyclopropyl, cyclopropyl, and cyclopropyl.

15. R Y But, -C 1 ~C 6 Alkylene-OR A , -OR A or -NR B R CC 2. The compound of claim 1,

16. R Y is —O—C, which may be substituted with 1 to 6 halogens; 1 ~C 6 Alkylene-C 1 ~C 6 The compound of claim 1 which is alkoxy.

17. The compound of claim 1, wherein the compound has formula (I-b): or a pharma- ceutically acceptable salt thereof, In the formula, D is selected from the group consisting of: Each R 1 , R W2 , R X , and R A is as defined in formula (I); The compound according to any one of claims 1, 2, 4 to 7, and 9 to 16.

18. D is 18. The compound of claim 17, 19. The compound of claim 1, wherein the compound has formula (I-c): or a pharma- ceutically acceptable salt thereof, In the formula, D is selected from the group consisting of: E is a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocyclyl, where the 5- to 6-membered heteroaryl or the 5- to 6-membered heterocyclyl is optionally substituted at one or more available carbons with 1-5 R G , and if the 5- to 6-membered heteroaryl or the 5- to 6-membered heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen can be optionally substituted with R N2 ; Each R 1 , A, R N2 , R W2 , and R G is as defined in formula (I); The compound according to any one of claims 1, 2, 4 to 7, and 9 to 16.

20. Formula (II): or a pharma- ceutically acceptable salt thereof, During the ceremony, D II is a bridged bicyclic cycloalkyl, a bridged bicyclic heterocyclyl, a 4- to 6-membered monocyclic cycloalkyl, a 4- to 6-membered monocyclic heterocyclyl, or a cubanyl, wherein each of the bridged bicyclic cycloalkyl, bridged bicyclic heterocyclyl, 4- to 6-membered monocyclic cycloalkyl, 4- to 6-membered monocyclic heterocyclyl, or cubanyl has from 1 to 4 R X-II and when the 4- to 6-membered monocyclic heterocyclyl or bridged bicyclic heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen is optionally substituted by R N1-II may be optionally replaced by U II is -NR 1-II C(O)- or -C(O)NR 1-II - and E II is absent, a bond, -NR 2-II C(O)-, -C(O)NR 2-II -, 5- to 6-membered heteroaryl, or 5- to 6-membered heterocyclyl, where the 5- to 6-membered heteroaryl or 5- to 6-membered heterocyclyl has 1 to 5 R G-II and when the 5- to 6-membered heteroaryl or 5- to 6-membered heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen is optionally substituted by R N2-II or E II teeth, And Y II is a 4- to 9-membered nitrogen-containing monocyclic, bridged bicyclic, fused bicyclic, or spirocyclic heterocyclyl, wherein the 4- to 9-membered monocyclic, bridged bicyclic, fused bicyclic, or spirocyclic heterocyclyl has 1 to 5 R G-II and when a 4- to 9-membered nitrogen-containing monocyclic, bridged bicyclic, fused bicyclic, or spirocyclic heterocyclyl contains a substitutable nitrogen moiety, the substitutable nitrogen is optionally substituted by R N2-II may be optionally replaced by L 1-II is a bond, C 1 ~C 6 Alkylene, 2- to 7-membered heteroalkylene, -NR N3-II - or -O-, where C 1 ~C 6 The alkylene or 2- to 7-membered heteroalkylene is 1 to 5 R L1-II may be substituted by L 2-II is absent or a bond, C 1 ~C 6 alkylene, 2- to 7-membered heteroalkylene, —C(O)—, or —O—, where 1 ~C 6 The alkylene or 2- to 7-membered heteroalkylene is 1 to 5 R L2-II may be substituted by Here, E II and L 2-II Both cannot be a bond and not exist at the same time. R 1-II is hydrogen or C 1 ~C 6 is alkyl, R 2-II is hydrogen or C 1 ~C 6 is alkyl, W II is phenyl or 5- to 6-membered heteroaryl, where the phenyl or 5- to 6-membered heteroaryl is selected from 1 to 5 R W-II and when the 5- to 6-membered heteroaryl contains a substitutable nitrogen moiety, the substitutable nitrogen can be substituted by R N4-II may be optionally replaced by A II is C 3 ~C 6 cycloalkyl, 4- to 6-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, where C 3 ~C 6 Cycloalkyl, phenyl, or 5- to 6-membered heteroaryl may have 1 to 5 R Y-II and when the 5- to 6-membered heteroaryl contains a substitutable nitrogen moiety, the substitutable nitrogen can be substituted by R N5-II may be optionally replaced by Each R L1-II are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, Amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, oxo, halo, cyano, -OR A-II , -NR B-II R C-II , -NR B-II C(O)R D-II , -C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OH, -C(O)OR D-II , -SR E-II , -S(O)R D-II , and -S(O) 2 R D-II is selected from the group consisting of Each R L2-II are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, Amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, oxo, halo, cyano, -OR A-II , -NR B-II R C-II , -NR B-II C(O)R D-II , -C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OH, -C(O)OR D-II , -SR E-II , -S(O)R D-II , and -S(O) 2 R D-II is selected from the group consisting of R N1-II is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, halo-C 2 ~C 6 Alkyl, Amino-C 2 ~C 6 Alkyl, cyano-C 2 ~C 6 Alkyl, —C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OR D-II , and -S(O) 2 R D-II is selected from the group consisting of R N2-II is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, halo-C 2 ~C 6 Alkyl, Amino-C 2 ~C 6 Alkyl, cyano-C 2 ~C 6 Alkyl, —C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OR D-II , and -S(O) 2 R D-II is selected from the group consisting of R N3-II is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, halo-C 2 ~C 6 Alkyl, Amino-C 2 ~C 6 Alkyl, cyano-C 2 ~C 6 Alkyl, —C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OR D-II , and -S(O) 2 R D-II is selected from the group consisting of R N4-II is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, C 1 ~C 6 Alkyl-C 1 ~C 6 Cycloalkyl, C 1 ~C 6 Alkenyl, —C(O)—C 1 ~C 6 Alkyl, —C(O)—C 1 ~C 6 Cycloalkyl, C 1 ~C 6 Alkyl-CO 2 H.C. 1 ~C 6 Alkyl-CO 2 -C 1 ~C 6 Alkyl, —C(O)—C 1 ~C3 alkyl-O-C 1 ~C 3 Alkyl-O-C 1 ~C 3 Alkyl, -C(O)-phenyl, -C(O)-heteroaryl, -C(O)-heterocyclyl, -S(O) 2 -C 1 ~C 6 Alkyl, -S(O) 2 -phenyl, -S(O) 2 -heteroaryl, -C(O)NR B-II R C-II and -C(O)OR D-II wherein: C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, C 1 ~C 6 Alkyl-C 1 ~C 6 Cycloalkyl, C 1 ~C 6 Alkenyl, C(O)-C 1 ~C 6 Alkyl, —C(O)—C 1 ~C 6 Cycloalkyl, C 1 ~C 6 Alkyl-CO 2 H.C. 1 ~C 6 Alkyl-CO 2 -C 1 ~C 6 Alkyl, -C(O)-heterocyclyl, and -S(O) 2 -C 1 ~C 6 The alkyl may be optionally substituted with one or more substituents, each of which may be independently fluoro, hydroxyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Alkyl (optionally substituted by 1, 2, or 3 fluorine atoms), and S(O) w-II C 1~6 alkyl (wherein w-II is 0, 1, or 2); and -C(O)-phenyl, -C(O)-heteroaryl, -S(O) 2 -phenyl, and -S(O) 2 Heteroaryl can be optionally substituted with one or more substituents, each of which is independently selected from halogen, hydroxyl, C 1 ~C 6 alkyl (optionally substituted by 1, 2 or 3 fluorine atoms), C 1 ~C 6 Alkoxy (optionally substituted by 1, 2 or 3 fluorine atoms), and S(O 2 ) N.R. B-II R C-II is selected from the group consisting of R N5-II is hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl, halo-C 2 ~C 6 Alkyl, Amino-C 2 ~C 6 Alkyl, cyano-C 2 ~C 6 Alkyl, —C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OR D-II , and -S(O) 2 R D-II is selected from the group consisting of Each R W-II are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, Hydroxy-C 2 ~C 6 Alkyl-O-, halo-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkoxy, amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, oxo, C=N-OH, halo, cyano, -OR A-II , -NR B-II R C-II , -NR B-II R CC-II , -NR B-II C(O)R D-II , -C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OH, -C(O)OR D-II , -SR E-II , -S(O)R D-II , and -S(O) 2 R D-II or Two R on adjacent atoms W-II The groups, together with the atoms to which they are attached, form a 3- to 7-membered fused cycloalkyl, a 3- to 7-membered fused heterocyclyl, a fused aryl, or a 5- to 6-membered fused heteroaryl, each of which is represented by 1 to 5 R X-II may be substituted by Each R X-II are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, Amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, oxo, halo, cyano, -OR A-II , -NR B-II R C-II , -NR B-II C(O)R D-II , -C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OH, -C(O)OR D-II , -SR E-II , -S(O)R D-II , and -S(O) 2 R D-II is selected from the group consisting of Each R Y-II are independently hydrogen, C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkoxy-C 1 ~C 6 Alkylene, Amino-C 1 ~C 6 Alkyl, cyano-C 1 ~C 6 Alkyl, halo, cyano, -OR A-II , -NR B-II R C-II , -NR B-II C(O)R D-II , -C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OH, -C(O)OR D-II , -S(R F-II ) m-II , -S(O)R D-II , -S(O) 2 R D-II , and G 1-II or Two R on adjacent atoms Y-II The groups, together with the atoms to which they are attached, form a 3- to 7-membered fused cycloalkyl, a 3- to 7-membered fused heterocyclyl, a fused aryl, or a 5- to 6-membered fused heteroaryl, each of which is represented by 1 to 5 R X-II may be substituted by Each G 1-II is independently 3- to 7-membered cycloalkyl, 3- to 7-membered heterocyclyl, aryl, or 5- to 6-membered heteroaryl, where each of the 3- to 7-membered cycloalkyl, 3- to 7-membered heterocyclyl, aryl, or 5- to 6-membered heteroaryl is selected from 1 to 3 R Z-II may be substituted by Each R Z-II is independently 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, halo, cyano, -OR A-II , -NR B-II R C-II , -NR B-II C(O)R D-II , -C(O)NR B-II R C-II , -C(O)R D-II , -C(O)OH, -C(O)OR D-II , and -S(O) 2 R D-II is selected from the group consisting of R A-II is, in each occurrence, independently hydrogen, C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkoxy-C 1 ~C 6 Alkylene, -C(O)NR B-II R C-II , -C(O)R D-II or -C(O)OR D-II and R B-II and R C-II Each of is independently hydrogen or C 1 ~C 6 is alkyl, or R B-II and R C-II together with the atoms to which they are attached, 1 to 3 R Z-II forming a 3- to 7-membered heterocyclyl ring optionally substituted by Each R CC-II is independently hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-CO 2 H.C. 1 ~C 6 Alkyl-CO 2 -C 1 ~C 6 Alkyl, C(O)C 1 ~C 6 Alkyl, S(O) 2 -C 1 ~C 6 and 3- to 6-membered cycloalkyl and 4- to 6-membered heterocyclyl, wherein the 3- to 6-membered cycloalkyl and 4- to 6-membered heterocyclyl may be optionally substituted by one or more substituents, each of which is independently selected from the group consisting of C 1 ~C 6 Alkyl, Hydroxy-C 1 ~C 6 Alkyl, halo-C 1 ~C 6 selected from the group consisting of alkyl, hydroxyl, halo, and -C(O)OH; Each R D-II is independently 1 ~C 6 Alkyl or halo-C 1 ~C 6 is alkyl, Each R E-II are independently hydrogen, C 1 ~C 6 Alkyl or halo-C 1 ~C 6 is alkyl, Each R F-II are independently hydrogen, C 1 ~C 6 alkyl, or halo; and Each R G-II are independently hydrogen, C 1 ~C 6 alkyl, halo, or oxo; However, D II When is a bridged bicyclic 5-membered cycloalkyl, E II is -NR 2-II C(O)-; A compound or a pharma- ceutically acceptable salt thereof.

21. below: and pharma- ceutically acceptable salts thereof.